Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
- 1 April 2016
- journal article
- review article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 141 (1), 86-94
- https://doi.org/10.1016/j.ygyno.2015.12.030
Abstract
No abstract availableKeywords
Funding Information
- Foundation for Women's Cancers
This publication has 140 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesionsCancer Immunology, Immunotherapy, 2012
- Uterine serous papillary carcinomas overexpress human trophoblast‐cell‐surface marker (trop‐2) and are highly sensitive to immunotherapy with hRS7, a humanized anti‐trop‐2 monoclonal antibodyCancer, 2011
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialInternational Journal of Cancer, 2010
- hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinomaBritish Journal of Cancer, 2010
- Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomasLaboratory Investigation, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- How dying cells alert the immune system to dangerNature Reviews Immunology, 2008
- Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia IIIGynecologic Oncology, 2007